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Background: A variety of systems have been developed to grade evidence and develop recommendations based
on the available evidence. However, development of guidelines for medical tests is especially challenging given the
typical indirectness of the evidence; direct evidence of the effects of testing on patient important outcomes is
usually absent. We compared grading systems for medical tests on how they use evidence in guideline
development.
Methods: We used a systematic strategy to look for grading systems specific to medical tests in PubMed,
professional guideline websites, via personal correspondence, and handsearching back references of key articles.
Using the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument as a starting point, we defined
two sets of characteristics to describe these systems: methodological and process ones. Methodological
characteristics are features relating to how evidence is gathered, appraised, and used in recommendations. Process
characteristics are those relating to the guideline development process. Data were extracted in duplicate and
differences resolved through discussion.
Results: Twelve grading systems could be included. All varied in the degree to which methodological and process
characteristics were addressed. Having a clinical scenario, identifying the care pathway and/or developing an
analytical framework, having explicit criteria for appraising and linking indirect evidence, and having explicit
methodologies for translating evidence into recommendations were least frequently addressed. Five systems at
most addressed these, to varying degrees of explicitness and completeness. Process wise, features most frequently
addressed included involvement of relevant professional groups (8/12), external peer review of completed
guidelines (9/12), and recommendations on methods for dissemination (8/12). Characteristics least often addressed
were whether the system was piloted (3/12) and funder information (3/12).
Conclusions: Five systems for grading evidence about medical tests in guideline development addressed to
differing degrees of explicitness the need for and appraisal of different bodies of evidence, the linking of such
evidence, and its translation into recommendations. At present, no one system addressed the full complexity of
gathering, assessing and linking different bodies of evidence.
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Guideline panels aim to develop recommendations
based on the best available evidence. In this process,
panels often grade the quality of the available evidence
[1]. Such an approach of systematically evaluating the
evidence and developing recommendations can reduce
bias and provide transparency to the guideline develop-
ment process with benefits to both guideline developers
and their target audiences [1]. This has led to the devel-
opment of a number of systems to grade evidence
according to its quality and the strength of recommen-
dations. A review of grading systems in 2002 reported
more than 60 available systems existing with wide varia-
tions in quality [2].
For intervention studies, the highest available evidence
comes from high quality systematic reviews of randomized
controlled trials that document the effect on patient
important outcomes, such as mortality, morbidity, or
functional health [3,4]. Guideline developers making rec-
ommendations on medical tests face a particularly unique
challenge of developing recommendations that take into
account patient important outcomes, because such direct
evidence of the effects of testing on outcomes often does
not exist. The available evidence base is often in the form
of studies of the analytical performance and the reprodu-
cibility of medical tests, and diagnostic accuracy studies
that estimate the sensitivity and specificity of a test in
comparison to the clinical reference standard for a disease
[5]. Yet, diagnostic test accuracy is not always appropriate
for expressing test performance. Guideline panels may be
interested in producing guidelines to address the use of
tests for testing disease susceptibility and risk stratifica-
tion, for staging a disease, monitoring its course for treat-
ment selection, and for surveillance after treatment. In
these applications, diagnostic test accuracy data may not
always be the most informative expression of test per-
formance [6,7].
Hence, when developing recommendations for a medical
test, guideline developers need to go beyond the analytical
performance and the accuracy of a test to consider conse-
quences of testing on patient outcomes, and to balance
benefits versus harms of testing, taking into account pa-
tient values and preferences and resource implications [8].
In addition, tests are never administered in isolation
but as part of a testing strategy. Guideline panels there-
fore need to consider the evidence in context of the
most likely testing strategy that includes the test that is
being evaluated, and from there make judgments on the
downstream patient consequences for further testing
and treatment [9]. All of this implies that guideline
panels need to use an evidence-grading system that al-
lows for the assessment of the quality and linkage of dif-
ferent types of indirect evidence in as transparent and
structured a manner as possible.Grading systems generally describe a subset of steps that
are a part of the overall guideline development process.
These are aspects concerned with formulating a key ques-
tion, systematically searching and gathering the related
evidence, and assessing its potential for bias, level of preci-
sion, and other elements of quality. The quality of the
evidence, in combination with a number of other factors,
guides the strength of the recommendation a guideline
panel should provide. Some evidence-grading systems can
go beyond these aspects and provide guidance on steps
that are part of the overall guideline development process,
such as those relating to stakeholder representation, dis-
semination and communication, and conflicts of interest.
It has previously been reported that a lack of standar-
dization in grading evidence and guideline development
methodology can lead to varying quality of guideline
recommendations [10,11]. A systematic review on the
guideline development process would be useful to the
guideline development community to help improve trans-
parency in the process.
Our aims were: first, to establish a comprehensive inven-
tory of evidence-grading systems for medical tests. We
wanted to compare the methods in each of these systems,
with a focus on those aspects related to appraising evidence,
linking different bodies of evidence, and translating evidence
into recommendations; as a secondary aim, we compared
the extent to which more general guideline development
processes were included in these grading systems.
Methods
Definitions of a guideline development process and
grading system
For the purposes of this review, we defined an evidence-
grading system to be a subset of the overall guideline
development process. We defined a guideline develop-
ment process to be one that begins by defining a topic
of interest, then conducting a scoping of the literature in
order to assess feasibility of the chosen topic. Once
feasibility is ascertained, specific key questions that the
guideline will address should be explicitly defined. This
is followed by systematically gathering the available evi-
dence and evaluating its quality; then formulating rec-
ommendations based on a number of factors such as the
quality of the gathered evidence, applicability, resource
issues, benefits versus harm, etc. We defined a grading
system to be the subset of this series of processes: those
that address aspects concerned with formulating a key
question, systematically searching and gathering the re-
lated evidence, then assessing its quality and formulating
recommendations (Figure 1).
Identification of grading systems
Because grading systems are often described and used
within the setting of a guideline development body, such as
Figure 1 Main steps in guideline development.
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(NICE), and are not always published in peer-reviewed
journals, we felt it necessary to used a multi-staged ap-
proach that involved searching various information plat-
forms up toMarch 2013 (Additional files 1 and 2).
To be included in our review, the description of a grading
system must explicitly state that it can be used for grading
evidence and making recommendations for medical tests.
The system must include a ‘levels of evidence’ and ‘strength
of recommendations’ table. Systems that were non-English
or employed only a checklist or other quality assessment
tool (e.g., QUADAS) to assess the quality of the evidence
and stopped there were excluded. Articles reporting a spe-
cific group process in developing a guideline, rather than a
grading system that could be used as a tool for developing
guidelines in general, were excluded.
We used a list of key articles as a starting point. The key art-
icle list contained a number of articles on available approaches
to evaluating evidence and making recommendations ingeneral and specific to medical tests. These articles were
identified by the authors of this study. We looked at how
these articles were indexed in Pubmed and analyzed
frequency of the terms used to index these articles. From
these, we picked a range of most frequently used terms,
which we then combined with a selection of free text
words relating to diagnostic test accuracy (Additional
file 1). We selected these terms from existing test accuracy
search filters [12,13] to reduce the number needed to
screen and the associated potential for error.
We also searched the websites of various guideline de-
velopers (Additional file 2). These were selected based on
citations from the key articles mentioned above and from
the experiences and knowledge of the authors through
informal discussions. The first author also screened do-
cuments on medical test guidelines retrieved via personal
correspondence.
We hand searched references of the key articles as well
as those articles that fitted the inclusion criteria that
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ding systems. The first author made a preliminary se-
lection of articles by checking the titles and/or abstracts.
A definite selection was made by the first author after
reading the full text of the selected articles.
Data extraction and presentation
We aimed to describe the identified grading systems in a
consistent, standard manner using relevant categories. As a
starting point, we referred to the categories in the Appraisal
of Guidelines for Research and Evaluation (AGREE) instru-
ment [14], a tool to assess the quality of clinical practice
guidelines. We adapted the domains and items from the
AGREE instrument via several rounds of informal discus-
sions among the authors. From this, we defined two sets of
assessment categories: methodological characteristics and
process characteristics (Tables 1 and 2).
Methodological characteristics are focused on the grad-
ing system within a guideline development process. These
were defined based on how explicit a grading system was
in describing how the evidence is gathered, its quality
assessed and recommendations derived. Here, we defined
six categories and a total of 23 subcategories (Table 1).
Process characteristics are basic guideline requirements re-
lating to the more general guideline development process
(Figure 1), such as the need to include relevant experts in
the guideline panel, providing clear and structured guid-
ance on the process to follow when making a guideline, on
the need for guideline panels to address editorial independ-
ence, and other process features. To reflect these, we de-
fined in total five categories and 12 subcategories (Table 2).
We tested the applicability of each category and subcat-
egory by extracting relevant information from a random
selection of grading systems. Data extraction was done in
duplicate and differences resolved through discussion be-
tween two reviewers. A third reviewer was involved when
consensus could not be reached. A review protocol detail-
ing the above methods was created by the first author
(Additional file 3). Since there was no research interven-
tion, our study was exempt from review by an ethics com-
mittee according to the Dutch Law.
Results
A total of 1,163 records were screened by title and/or
abstract resulting in 64 full text records being retrieved
(Figure 2). Twelve grading systems [15-31] were finally
identified for inclusion, two of which—Evaluation of
Genomic Applications in Practice and Prevention initiative
(EGAPP) and NICE’s Diagnostic Assessment Programme
(DAP)—were specific to medical tests [22,26]. We included
the NICE DAP as at the time of this review it was unclear
if NICE would also adopted the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
methodology for its diagnostic guidelines [32].Methodological characteristics
Structuring the search
EGAPP was the most comprehensive for this category,
covering six out of the seven subcategories, followed by
NICE DAP and the U.S. Preventive Services Task Force
(USPSTF), which each addressed five out of the seven
subcategories listed (Figure 3). The subcategories ‘Pre-
paratory steps prior to evidence collection’ (8/12), ‘Defin-
ing outcomes of interest’ (7/12), ‘Scoping the literature’
(6/12), ‘Formulating a Patient Intervention Comparison
Outcome (PICO) styled key questions’ (5/12) were the
most commonly covered features in this category across
all the grading systems (Figure 3). The subcategory ‘Clin-
ical scenario’ (EGAPP and NICE DAP) and ‘Analytical
framework’ (EGAPP and USPSTF) featured only in two
grading systems (Figure 3). The NICE DAP was the only
system that included a feature called the ‘care pathway,’
defined as a pathway that shows the entire sequence of
tests and treatments related to the test being evaluated.
Searching for the evidence
Having an explicit search methodology as part of evidence
gathering was addressed in seven out of 12 systems, to
varying degrees of detail. Less than half of the grading sys-
tems were explicit on the number and type of databases
the search should include (5/12) (Figure 3).
Types of evidence
The European League Against Rheumatism (EULAR),
European Society of Cardiology (ESC), Institute for Clin-
ical Systems Improvement (ICSI) and the Oxford Centre
for Evidence-based Medicine (OCEMB) were not explicit
on the types of evidence that needed to be collected. Half
of the systems (6/12) specified the need to collect patient
important outcome data of which only three (EGAPP,
GRADE and NICE DAP) explicitly required other types of
evidence to be gathered such as costs, quality of life, con-
textual implications of the test such as ethical, legal, and
social implications and information on resource use.
Appraising the evidence
All systems except one (ESC) required users to grade
the quality of the evidence at the individual study level,
nine of which outlined specific criteria to be used.
Nine systems also explicitly required the evidence to be
graded collectively as a ‘body of evidence,’ and seven pro-
vided specific criteria by which this could be done. Only
NICE DAP and the USPSTF provided explicit guidance
on appraising different bodies of evidence. The EGAPP
acknowledges in its grading system the need to link and
appraise different types of evidence in the appraisal and
guideline development for medical tests, given that ac-
curacy alone is indirect evidence on patient important
Table 1 Methodological characteristics
No. Category/sub category Description
Methodological characteristics: features relating to how evidence is gathered, appraised and recommendations developed
1 Structuring the search
1a-g Preparatory steps prior to evidence
collection
Preparatory steps are clearly outlined prior to beginning the literature search. Preparatory
steps defined as any step that defines the remit of the guideline, such as scoping of the
literature*, identify key question(s), define outcomes of importance, create a clinical scenario/
care pathway and/or analytical framework **
2 Searching for the evidence
2a Explicit methodology exists A systematic search strategy (e.g., a systematic literature review) for gathering the evidence is
described
2b Minimum no. of databases A minimum no. of databases is specified which need to be included in the search strategy
3 Types of evidence gathered
3a-c Accuracy data The search for evidence extends beyond test accuracy to include other evidence such as
patient important outcomes (e.g., quality of life), cost and resource, legal and ethical issues etc.
Patient important outcome data
Other
4 Appraising the evidence
4a 1st tier (individual study level) Evidence is appraised at the individual study level
4b 2nd tier (as a body of evidence e.g.,
systematic review)
Evidence is appraised as a total body (i.e., systematic review)
4c 3rd tier (combining different bodies
of evidence)
Different bodies of evidence are brought together and appraised (i.e., combining evidence
derived from different systematic reviews or other forms of evidence reports on cost, quality
of life measures etc.)
5 Explicit criteria for appraising
the evidence
5a-c 1 tier (individual study) Criteria used to appraise the evidence at each tier is explicit. For instance, is there a quality
checklist used, what are the levels of evidence, is appraisal done in duplicate by different
reviewers, is there an evidence table compiled, what other criteria are used to assess
evidence quality
2 tier (as a body of evidence
e.g., systematic review)
3 tier (combing different bodies of
evidence)
6 Formulating recommendations
6a Methods on how recommendations
are derived
Explicit method(s) exist to formulate the recommendations and how final decisions are arrived
at. Methods include for example, a voting system, formal consensus techniques (e.g., Delphi,
Glaser techniques). Areas of disagreement and methods of resolving them should be specified
6b Guidance on wording of
recommendations
Guidance is provided on how recommendations should be worded to provide clear,
unambiguous recommendations
6c Patient important outcomes
considered
Patient important outcomes are explicitly considered in the recommendation formulation stage
6d A method exists to translate indirect
evidence into recommendations
An explicit methodology exists on how indirect evidence (i.e., accuracy data) is translated
into recommendations
6e Applicability of recommendations
considered
Potential organizational barriers and cost implications of recommendations are considered. For
instance, applying the recommendations may require changes in the current organization of
care within a service or a clinic which may be a barrier to using them in daily practice.
Recommendations may require additional resources in order to be applied. For example, there
may be a need for specialized staff, new equipment, or an expensive drug treatment
Total 6 categories/23 subcategories
*Scoping of the literature is defined as a very broad search of the literature relevant to the condition that is to be the topic of the guideline. No attempt is made
to focus on specific questions at this stage. The intention is only to establish the general extent of the literature in the clinical area to see if there is likely to be
sufficient good quality evidence to make evidence based guideline feasible.
**A clinical scenario is defined as a scenario that addresses the intended use of test including setting e.g., primary or specialist care; how test will be applied
e.g., screening, diagnosis; who will be tested e.g., general population or high risk groups.
**Care pathway is defined as the diagnostic sequences, treatments, monitoring, retreatment, treatment for side effects and complications that are part of the test-
treatment pathway. A flow chart or other diagram can be used to illustrate the pathway.
**Analytical framework is defined as an overarching framework showing linkages of the clinical scenario, the intermediate and health outcomes of interest, and
the key questions to be addressed.
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Table 2 Process characteristics
No. Category/sub category Definition
Process characteristics: basic guideline requirements relating to the guideline development process
1 Scope & purpose
1a Overall aim The overall aim of system is explicit. The system is specific to medical tests
2 Stakeholders
2a Relevant professional groups The system requires involvement of relevant professional groups
2b Piloted among users The system has been piloted among guideline developers and reports on user feedback
3 Clarity & presentation
3a Clear organization and content layout The system contains a chronological description of the process for developing guidelines.
3b Recommendations easily identifiable The system promotes a clear and structured layout for presenting recommendations e.g.,
summarized in a box, typed in bold, underlined or presented as flow charts or algorithms
3c Examples provided The system provides adequate examples in the form of, tables, forms, layouts of evidence
summaries e.g., in GRADE known as ‘’evidence profile’
3d Glossary The system includes a glossary explaining terminology
4 Dissemination & communication
4a External peer review recommended The system recommends external peer review of completed guidelines
4b Recommends methods for
dissemination
The system recommends methods for dissemination and communicated of completed
guidelines to target audience(s)
4c Procedure for updating guideline The system provides an explicit procedure for updating the guideline
5 Editorial independence
5a Addresses conflicts of interest The system specifies the need to address conflicts of interest of guideline members and
information on funding
5b Addresses funders
Total 5 categories/12 subcategories
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by which this can be done.
Formulating recommendations
Methods for making recommendations were explicitly pro-
vided in most systems (9/12). Only six systems reported the
inclusion of patient important data when making recom-
mendations. Explicit methods for translating accuracy
evidence to recommendations were provided in only three
of the 12 systems (GRADE, NICE DAP and the National
Health andMedical Research Council (NHMRC)).
Current publications on applying GRADE to diagnostic
tests describe the use of a considered judgment process
where the guideline panel makes an informed judgment
based on presumed patient important outcomes for pa-
tients with true and false positive test results, and true and
false negative test results [17,18]. Other factors considered
are quality of the evidence, benefits versus harms of the
test, patient values and preferences, and cost [17]. In the
NICE DAP manual, the guideline panel takes into account
the evidence from three aspects when making recommen-
dations: diagnostic accuracy evidence, clinical effectiveness
and cost effectiveness [26] (Table 3). Cost-effectiveness of
the diagnostic technology is the aspect most explicitly
assessed through the use of models, although detailsof how the models are generated and how the related evi-
dence is gathered are not described. The NICE DAP man-
ual explicitly states that the extent to which the
considerations described under diagnostic accuracy and
clinical effectiveness are taken into account are a matter
of the guideline panel’s discretion.
The NHMRC’s process of moving from evidence to
making recommendations is the least explicit, in compari-
son to the GRADE and NICE DAP processes. The guide-
line panel rates the evidence according to five factors:
evidence base (as determined by the levels of evidence
hierarchy with systematic reviews having the highest
level), consistency, clinical impact, generalizability, and ap-
plicability (Table 3). With the exception of the evidence
base, an explicit methodology as to how the panel should
rate these factors is absent. It appears here again that a
considered judgment process is utilized based on the dis-
cretion of the guideline panel.
Process characteristics
Characteristics most likely to be addressed in the 12
grading systems were the need for involvement of rele-
vant professional groups during guideline development
(8/12), the need for external peer review of completed
guidelines (9/12), and the inclusion of recommendations
1,163 records after duplicates removed
1,163 records screened
64 full records accessed for eligibility
1,099 records 
excluded
52 records excluded as these 
were:






did not contain a ‘levels of 
evidence table’ and strength 
of recommendations 
grading
contained only checklists 
for grading the evidence 
articles not related to 
grading systems
not explicit on use for 
medical test guideline 
development
12 records included
1,201 records identified 
through PubMed searching
75 additional records identified 
from other sources (hand searching, 
personal correspondence, 
professional websites)
Figure 2 Summary of search strategy.
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to target audiences (8/12) (Figure 4). The overall aim of
11 out of the 12 grading systems was explicitly stated.
Other characteristics commonly addressed included
the presence of a clear content layout and organization
(7/12), the presence of a procedure for updating guide-
lines (7/12), and the need for guideline developers to ad-
dress conflicts of interest in a guideline (7/12).
Piloting of the grading system and information on
funding were the least likely process characteristics
reported, with only three of the 12 systems (Figure 4)
fulfilling this category. Although we know (via personal
correspondence) that the GRADE system has been
piloted at a number of international meetings and for-
ums, it was not explicitly reported in the publications
assessed for this work [15-17]. Other less commonly
addressed features include the provision of a glossary
(4/12), key recommendations being easily identifiable inthe guideline (4/12), and provision of example tables,
forms, and other layouts to guide developers on the struc-
ture for developing a guideline (4/12) (Figure 4).
Overall
All 12 grading systems varied in the extent to which they
addressed process and methodological characteristics.
On the whole, we found a wide variation in terminolo-
gies used. Methodologically, out of the 23 subcategories
defined, the EGAPP (19/23) followed by the USPSTF
(18/23) and NICE (17/23) were the most comprehensive
(Figure 3). The ESC was the least comprehensive where
none of the 23 subcategories were met followed by ICSI
(4/23), EULAR (6/23) and Strength of Recommendation
Taxonomy (SORT) (6/23) (Figure 5a). The Scottish Inter-
collegiate Guidelines Network (SIGN), NHMRC and the
American Heart Association Practice Guidelines (AHAPG)
systems were the most comprehensive when it came to
Figure 3 Methodological characteristics.
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subcategories defined and AHAPG and NHMRC nine out
of 12 each. OCEMB, SORT, GRADE and ICSI addressed
the least number of process features (Figure 5b).
Discussion
In this review, we identified 12 eligible evidence-grading
systems that could be used by guideline developers to
develop guidelines for medical tests. The EGAPP, USPSTF,
NICE, GRADE, andNHMRC systems addressed, to differingdegrees of explicitness, the need for and appraisal of dif-
ferent bodies of evidence, the linking of such evidence and
its translation into recommendations. However, no one
system adequately addressed the complexity of gathering,
assessing, and linking different bodies of evidence, which
is one of the challenges guideline developers of medical
tests face. All 12 varied in basic guideline development
features.
We have been able to include a number of grading
systems available to guideline developers [1,33]. While we
employed multifaceted search strategies in an attempt to
be as comprehensive as possible, it is possible we have not
identified all systems available. Similar difficulties of gath-
ering grading systems have been reported previously
[2,10]. Because we found no single repository that stores
such systems, guideline developers looking for available
grading systems or those interested in comparing such
systems may face similar challenges. The wide variation in
terminology usage across the systems is an issue raised
previously by other researchers [10].
To describe the process characteristics, we felt adapting
the domains from the AGREE instrument was the most
appropriate, given that this is an instrument developed to
assess the quality of clinical guidelines. However, AGREE
was developed to assess the quality of the final product,
whereas we looked at the guideline development process
and thus we adapted the domains to fit this aim.
For the methodological characteristics relating to how
evidence is gathered, assessed, and recommendations de-
rived, the AGREE instrument does not address these
aspects in a manner that was specific to the issues in med-
ical test guideline development. The domain on ‘Rigor of
Development’ contains eight items relating to how the evi-
dence is gathered, assessed, and how recommendations
are formulated [14]. While some of the items in the do-
main relate to how the evidence is appraised and whether
an explicit methodology exists between the evidence and
recommendations, we felt that one of the main issues in
guideline development for tests—relating to the assess-
ment of and linking of different bodies of evidence—is not
addressed explicitly. Because there is currently no other in-
strument for appraising the quality of an evidence-grading
system, or for defining the essential features it should con-
tain [10], we had to define these categories based on the
authors’ experiences and knowledge on the issues relating
to challenges in medical test guideline development.
The objective of this review was not to make an ana-
lytical appraisal of the different grading systems avail-
able. To address that objective adequately is beyond the
scope of this review. As such, the tables describing the
systems in this review may not always appropriately
discriminate the individual strengths and weaknesses of
each system. It may also be worthwhile to note that not
all of the systems included in this review may have been
Table 3 Summary of main features in GRADE, NICE DAP and the NHMRC systems for moving from evidence to making
recommendations
GRADE NHMRC system NICE DAP system
Evidence on accuracy Using a considered judgment
process, derive presumed PIO for the






- Number of studies - Inclusiveness of underlying data
- Level of evidence - Meta analysis techniques
- Risk of bias - Cut off points





- Quality of evidence gathered Clinical impact: not explicitly
explained
Clinical effectiveness:
- Patient’s values and preferences Generalisibility: how well does
the body of evidence match the
the body of evidence match
thepopulation and clinical setting
being targeted by the guideline
- Nature and quality of evidence
derived from expert,
- Costs Applicability: is the evidence
body relevant to the Australian
healthcare context and culture
- Lay members and stakeholder
judgments
- Benefits vs harms Evidence base: - Uncertainty of evidence and
differences in evidence gathered
under research conditions vs in
actual
- Number of studies - Clinical practice
- Level of evidence - Greater benefits or harms in
subgroups
- Risk of bias - Risks and /or benefits of
technology from patients
perspective
- Position of technology in overall





- Impact on patient outcomes
- Robustness and appropriateness of
model
- Plausibility of inputs and
assumptions made in economic
model
- Evaluation of the modeling
approach and related evidence
effectiveness ratios (ICERs)
generated by the models
- Range and plausibility of the
incremental cost-
- Likelihood of decision error and
consequences
- Degree of clinical need of patients
under consideration
- Potential for long term benefits of
innovation
Gopalakrishna et al. Implementation Science 2013, 8:78 Page 9 of 14
http://www.implementationscience.com/content/8/1/78
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they may have addressed process features poorly.
Two other prominent reviews of evidence-grading sys-
tems have been reported in the literature [1,2] A number
of differences in scope and methodology exist between
the review conducted by the Agency for Healthcare Re-
search and Quality (AHRQ) [2] and that by the GRADEWorking Group [1]. While the AHRQ review employed
a systematic search strategy, it was not limited to identi-
fying only systems applicable to medical tests. The re-
view’s objective was to describe systems used to grade
evidence. Hence checklists and such similar tools were
included. The review was not concerned with the devel-
opment of recommendations or the overall guideline
Figure 5 Overview: (a) methodological characteristics (b) process characteristics.
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did not employ a systematic search strategy. It was
limited to six prominent rating systems known to the
authors. Similar to the AHRQ review, it was focused on
appraising each system on the aspect of rating evidence
although the authors did extend this to include develop-
ment of recommendations but stopped there. Neither
review was limited to systems specific for medical tests.
Only three of the grading systems included in this re-
view [15,23,26] had been user tested, which could explain
why the other user test related features such as the avail-
ability of a glossary, template forms and tables, and key
recommendations being easily identifiable were poorly
addressed across the 12 systems. The extensive user test-
ing done on the GRADE system for interventions and the
incorporation of user feedback into its system could be
one factor that has contributed to its popularity among
guideline developers [33,34].When it came to grading systems developed by specialty
societies (AHAPG, ESC, EULAR, and SORT), these
tended to be more comprehensive in addressing process
characteristics related to guideline development, but were
less thorough in covering features important for systemat-
ically gathering, assessing and making recommendations
(Figure 3) (Figure 5a). For example, the AHAPG was the
second most comprehensive system among the 12 grading
systems, covering nine out of the 12 process characteris-
tics (Figure 5b), but covered less than half of the methodo-
logical characteristics defined (10/23) (Figure 5a). Perhaps
the starkest contrast was in the system by ESC where
none of the 23 methodological categories were addressed.
In comparison, the system fulfilled eight out of the 12
process subcategories, implying that grading systems de-
veloped by such organizations tended to be methodologic-
ally less comprehensive. This could explain the findings of
Burgers et al. and Grilli et al. who report that guidelines
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methodological quality compared to those produced by
major guideline bodies [35,36].
Given the complexities in medical test guideline devel-
opment, we defined a number of methodological charac-
teristics as being particularly pertinent to medical tests
and different to the methods for guideline development
for interventions. The definition of clearly defined key
questions is a first step in any guideline development.
Because medical tests are often part of a test/treatment
strategy, a PICO (Patient-Intervention-Comparison-Out-
come) [37] styled key question is important but may not
be adequate. In the NICE, EGAPP, and USPSTF systems,
the PICO is supplemented with a broader framework.
The clinical scenario, which both the EGAPP and NICE
systems contain, addresses the intended use of the test,
including the clinical setting (e.g., primary care, specialty
settings), how the test will be applied (e.g., diagnosis or
screening), and who will be tested (e.g., general popula-
tion or selected high risk individuals). Both the EGAPP
and USPSTF go one step further to put the clinical
scenario in question into the context of an analytical
framework, which essentially is an overarching key ques-
tion on clinical utility, i.e., whether there is direct evi-
dence that using the test leads to clinically meaningful
improvement in outcomes.
While the NICE system does not contain an analytical
framework, it defines a care pathway within which the
clinical scenario is covered. The care pathway addresses
a broader view on the test-treatment pathway that in-
cludes all aspects related to the application of the test
and treatment sequences that may follow such as moni-
toring, retreatment, treatment for side effects and com-
plications that may be experienced by the patient as a
result of the test.
‘Which of the above preparatory steps is best?’ is a dif-
ficult question to answer. The NICE, EGAPP, and
USPSTF obviously go beyond the typical PICO-styled
key question definition, and would make for a more
comprehensive assessment of a medical test than a grad-
ing system that does not include such components in its
preparatory phase. The inclusion of features such as the
clinical scenario, analytical framework, and/or care path-
way helps to address the point reiterated many times
that an evaluation of a test in context of its test-
treatment pathway is more informative than the evalu-
ation of its accuracy alone [9,38,39].
Rating the quality of evidence is another aspect in
grading systems that is challenging for medical tests
compared to interventions. Because of the indirectness
of evidence about tests relative to patient important
outcomes, different bodies of evidence may need to be
gathered and assessed that are relevant to the patient
outcomes being considered by the guideline panel. Oftenthese data are either lacking or when available maybe in
the form of observational studies that, in the level of
hierarchy of studies, is classified as low quality [17].
Grading systems therefore need to provide explicit guid-
ance to guideline panels on the types of evidence that
need to be gathered in the absence of evidence of the
effects on patient outcomes. Guidance is also needed on
explicit methods on how these data can be assessed and
linked to other bodies of evidence. Less than one-half of
the grading systems in this review were explicit on the
need for patient important data. Even fewer (three sys-
tems) mentioned the need to gather other types of data
such as costs and resource utilization. EGAPP and NICE
systems, both specific for medical tests, were the only two
systems that were explicit on the need to gather such data,
although they do not provide clear criteria on how such
data should be evaluated. While we did not find this to be
explicit in the current publications on GRADE for diag-
nostics [15-18], we are aware that this is an area currently
being addressed by the GRADE Working Group (via per-
sonal correspondence).
A considered judgment process was the most com-
monly used method to move from evidence to making
recommendations. GRADE, NHMRC, and NICE were
the only three systems that provided clear criteria that
should be considered when making this transition. Al-
though GRADE’s process was the simplest and clearest
amongst the three, none of the three systems involved
an explicit method by which the different bodies of evi-
dence could be translated into recommendations. NICE’s
economic modeling, which formed one aspect of the
process of moving from evidence to recommendations,
was the only aspect that involved an explicit, structured
methodology with clear cut-off points and guidance on
the different recommendations to make based on the
model thresholds [26].
Conclusion
Clear guidance for evaluating, linking, and making recom-
mendations based on different bodies of evidence beyond
test accuracy is lacking in grading systems available today.
The EGAPP, USPSTF, NICE, GRADE, andNHMRC systems
address these aspects to varying degrees of comprehensive-
ness. There is a clear need for closer analysis of these features
in each of these systems and for more targeted user testing
amongmedical test guideline developers.
Existing grading systems for medical tests vary consid-
erably in the extent to which they cover basic guideline
quality requirements. The guideline development com-
munity can benefit from consensus and standardization
regarding the basic features a grading system should
cover. This could help to achieve consistency, improve
transparency and, ultimately lead to the production of
better quality guidelines.
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